Answers are grounded in this paper and cite their sources.
Sir, Tigecycline is a broad-spectrum glycylcycline antibiotic, derived from the tetracycline minocycline. It was licensed in the USA in 2005 and in the European Union in 2006 for use in the treatment of complicated skin and soft tissue infections and in complicated intra-abdominal infections. Acquired ribosomal protection [e.g. tet(M)] and efflux [tet(A–E)] tetracycline resistance mechanisms do not compromise tigecycline,1–3 which may be useful in infections due to multiresistant Enterobacteriaceae. The European Committee on Antimicrobial Susceptibility Testing/European Medicines Agency (EUCAST/EMA) have defined tigecycline MIC breakpoints as follows: Streptococcus spp. and Enterococcus spp., susceptible ≤0.25 mg/L and resistant >0.5 mg/L; Staphylococcus spp., susceptible ≤0.5 mg/L and resistant >0.5 mg/L; and Enterobacteriaceae, susceptible ≤1 mg/L and resistant >2 mg/L. The US FDA has set somewhat higher breakpoints for the Enterobacteriaceae at susceptible ≤2 mg/L and resistant >4 mg/L. The EUCAST/EMA values have been accepted by the BSAC, whilst the CLSI has yet to set values. A 15 µg tigecycline disc has been proposed for universal use in susceptibility testing and zone breakpoints for its use with the BSAC method using IsoSensitest agar have been published.4 The BSAC disc method is, however, little used outside the UK. Many European laboratories use the CLSI disc method, with heavier inocula on Mueller–Hinton agar, but now, owing to the legal status of the EMA, must seek to have this agree with EUCAST MIC breakpoints rather than those of the CLSI.5 The present project therefore aimed to identify the zone breakpoints for the CLSI method that best correspond to the EUCAST MIC breakpoints. Whilst the work was underway, EUCAST themselves published provisional zone breakpoints for 15 µg tigecycline discs, and the present analysis compares the performance of their criteria and those we have derived. Isolates (n = 357) were selected from the BSAC bacteraemia survey collection,6 which collects 10–20 isolates of each of 12 species groups per annum from 25 hospital laboratories in the UK and Ireland. These were supplemented with additional isolates with tigecycline MICs >1 mg/L from other survey collections and from among reference submissions to the Antibiotic Resistance Monitoring and Reference Laboratory. MIC distributions for the collection are shown in Table 1. The organisms comprised: Enterobacteriaceae (excluding Proteus spp.) (n = 163); α/β-haemolytic streptococci (n = 89); staphylococci (n = 65); and enterococci (n = 40). Zones and agar dilution MICs were determined by CLSI methods, and reviewed against the breakpoints of EUCAST.7 Tigecycline MIC distribution of the isolate collection Tigecycline MIC distribution of the isolate collection Based on error minimization, we propose the disc zone breakpoints shown in Table 2. With a total of 194 tests, Gram-positive organisms gave three very major errors (resistant isolates reported as susceptible), 12 major errors (susceptible isolates reported as resistant) and 28 minor errors (an intermediate isolate found susceptible or resistant and vice versa). Using the same dataset, EUCAST's proposed disc breakpoints (Table 2),7 led to 13 very major errors, no major errors and 34 minor errors for Gram-positive bacteria. Zone breakpoints (mm) derived here and as proposed by EUCAST7 S, susceptible; I, intermediate; R, resistant; NA, not applicable. Zone breakpoints (mm) derived here and as proposed by EUCAST7 S, susceptible; I, intermediate; R, resistant; NA, not applicable. Assigning breakpoints for the Enterobacteriaceae is more complex, because MICs of 2 mg/L (intermediate by EUCAST/EMA criteria) fall within the upper end of the normal distribution for Klebsiella spp. Error minimization analysis indicated for the 163 Enterobacteriaceae that zone breakpoints of susceptible ≥21 mm and resistant ≤17 mm produced the best agreement with MIC categorization (Table 1), with only one very major error and one major error. However, 38/163 (23.3%) isolates gave minor errors. Using the provisional EUCAST disc breakpoints7 led to 8/163 (4.9%) very major errors, no major errors and 59/163 (36%) minor errors among the Enterobacteriaceae. In summary, and with the zone breakpoints derived here, the 15 µg tigecycline discs adequately differentiated between susceptible, intermediate and resistant for most Gram-positive organisms; though there were many minor errors for Enterobacteriaceae isolates. Differentiation of the susceptible/intermediate border was difficult for some genera (e.g. Klebsiella spp.) and it is prudent to determine the MICs (e.g. by Etest) for isolates giving zones around this border. The breakpoints proposed here are more conservative than the recently released EUCAST values,7 producing fewer very major errors [4 (1.12%) versus 21 (5.8%)] or minor errors [66 (18.4%) versus 93 (26%)], but more major errors [13 (3.6%) versus 0 (0%)]. Since very major errors are the greatest concern in susceptibility testing, we suggest that the values proposed here should be preferred. This work was supported by Wyeth. D. M. L. has shareholdings, or acts as enduring attorney for a shareholder, in AstraZeneca, Dechra, EcoAnimal Health, GlaxoSmithKline, Schering-Plough and Pfizer, and he has had research contracts or conference finance in the past 3 years from AstraZeneca, Calixa, Cerexa, Johnson & Johnson, Merck, Novartis, Novexel, Pfizer, Phico, Theravance and Wyeth. All authors are employed by the HPA and are influenced by the HPA's views on antibiotic usage. Isolates for this work were provided by the BSAC Resistance Surveillance Project.
No takes yet. Share an insight, caveat, or question.
Hope et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: